zintick

Disc Medicine IRON

Disc Medicine, Inc. · Nasdaq · Pharmaceutical Preparations

$83.20+4.13%close on Oct. 28, 2026 · volume 1.1M · Yahoo Finance

Price, last 47 sessions

$60.00$70.00$80.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 28, 2026 · high $83.20 · low $55.74 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Oct. 21, 2026Kevin Bitterman
director · indirect
Sold
10b5-1 plan
25,519$80.23$2.05 million
Oct. 20, 2026Kevin Bitterman
director · indirect
Sold
10b5-1 plan
5,312$79.95$424,694
Oct. 19, 2026Kevin Bitterman
director · indirect
Sold
10b5-1 plan
10,994$79.97$879,190
Sept. 11, 2026Kevin Bitterman
director
Sold27,136$70.11$1.90 million
Sept. 4, 2026Kevin Bitterman
director · indirect
Sold
10b5-1 plan
1,689$79.96$135,052
Sept. 3, 2026Kevin Bitterman
director · indirect
Sold
10b5-1 plan
5,203$79.98$416,136
Sept. 2, 2026Kevin Bitterman
director · indirect
Sold
10b5-1 plan
49,164$80.17
$80.17-$80.98
$3.94 million
Sept. 1, 2026Kevin Bitterman
director · indirect
Sold
10b5-1 plan
129$79.95$10,314
Aug. 25, 2026Jonathan Yen-Wen Yu
Chief Operating Officer
Sold
10b5-1 plan
8,796$83.12$731,092
Aug. 24, 2026Jonathan Yen-Wen Yu
Chief Operating Officer
Sold
10b5-1 plan
300$82.53$24,760
Aug. 17, 2026John D. Quisel
Chief Executive Officer, director
Sold
10b5-1 plan
33,000$79.15
$78.11-$79.84
$2.61 million
Aug. 12, 2026Jonathan Yen-Wen Yu
Chief Operating Officer
Sold
10b5-1 plan
804$82.64$66,445

Latest 12 of 13. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 18 →
  • SCHEDULE 13D/AOct. 26, 2026, 5:52 p.m. ETView on SEC.gov
  • 8-KOct. 22, 2026, 5:11 p.m. ETView on SEC.gov

    Entry into a material definitive agreement · Results of operations and financial condition · Other events · Financial statements and exhibits

    AI summary, unreviewedDisc Medicine Prices Upsized $450 Million Common Stock Offering at $75.00 per Share, Reports $682.8 Million Preliminary Cash at September 30, 2026

  • 4Oct. 21, 2026, 5:33 p.m. ETView on SEC.gov
  • 424B5Oct. 21, 2026, 5:21 p.m. ETView on SEC.gov
  • 424B5Oct. 19, 2026, 5:42 p.m. ETView on SEC.gov
  • 8-KOct. 19, 2026, 7:08 a.m. ETView on SEC.gov

    Regulation FD disclosure · Other events · Financial statements and exhibits

    AI summary, unreviewedDisc Medicine Reports Positive Phase 3 APOLLO Topline Results for Bitopertin in EPP, Meeting All Primary and Secondary Endpoints

  • 4Sept. 16, 2026, 6:44 p.m. ETView on SEC.gov
  • 4Sept. 15, 2026, 4:30 p.m. ETView on SEC.gov